StereotaxisSTXS
About: Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.
Employees: 122
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
576% more call options, than puts
Call options by funds: $284K | Put options by funds: $42K
171% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 7
33% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 4 (+1) [Q3]
32% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 19
17% more funds holding
Funds holding: 71 [Q2] → 83 (+12) [Q3]
13% more capital invested
Capital invested by funds: $73.2M [Q2] → $82.4M (+$9.19M) [Q3]
0.97% less ownership
Funds ownership: 48.66% [Q2] → 47.69% (-0.97%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for STXS.
Financial journalist opinion
Based on 7 articles about STXS published over the past 30 days
